Bicycle Reports Q1 Revenue of $887K, Below Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy BCYC?
Reports Q1 revenue $887k, consensus $7.5M. "The data we reported in the first quarter continues to provide further validation of the potential of our Bicycle technology to deliver oncology therapeutics with improved benefit/risk profiles compared to existing modalities," said Bicycle CEO Kevin Lee, Ph.D. "We are excited by the emerging profile of our EphA2 drug conjugate, nuzefatide pevedotin, which we have now tested in over 150 patients to date, both as a monotherapy and in combination with a checkpoint inhibitor. Nuzefatide has been shown to be generally well tolerated at clinically active doses, in contrast to previous attempts to drug this target with other modalities. We believe these data, together with those presented at AACR, provide a strong rationale for advancing the development of nuzefatide in pancreatic cancer, and we are pleased to have recently dosed our first patient in our Phase 2 trial. In addition to this, the preliminary data we have reported from our Duravelo-2 program demonstrate zelenectide pevedotin to also be clinically active with a differentiated safety profile, providing convincing evidence that Bicycle drug conjugates may exhibit a fundamentally different tolerability profile to that seen with antibody-based approaches, and support our mission of helping patients not only to live longer but also to live well."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BCYC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BCYC
Wall Street analysts forecast BCYC stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 4.900
Low
24.00
Averages
24.00
High
24.00
Current: 4.900
Low
24.00
Averages
24.00
High
24.00
About BCYC
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bicycle Therapeutics Reports Q1 Earnings Miss
- Earnings Report Disappointment: Bicycle Therapeutics reported a Q1 GAAP EPS of -$0.87, missing estimates by $0.20, indicating ongoing challenges in profitability that could undermine investor confidence.
- Significant Revenue Decline: The company generated $0.89M in revenue for Q1, a staggering 91.1% year-over-year drop, falling short of expectations by $6.61M, which highlights severe deficiencies in market demand and product sales that may lead to liquidity issues in the future.
- Cash Reserves Status: As of March 31, 2026, Bicycle Therapeutics held $559.5M in cash and cash equivalents, with an expected runway into 2030, providing a buffer for operations despite current financial strains.
- Strategic Shift and Layoffs: The company announced a shift in priorities and layoffs, indicating proactive measures to address its financial challenges, aiming to enhance operational efficiency through optimized resource allocation.
See More
Bicycle Therapeutics Presents Five Abstracts at AACR Annual Meeting 2026
- Presentation Schedule: Bicycle Therapeutics will showcase five studies at the AACR Annual Meeting 2026 from April 17-22, highlighting its latest advancements in cancer therapeutics, which is expected to attract industry attention and enhance the company's visibility.
- Key Research Findings: One oral presentation will focus on the anti-tumor activity of BT5528 in head and neck squamous cell carcinoma models, demonstrating its potential in preclinical studies and possibly laying the groundwork for subsequent clinical trials.
- Diverse Research Topics: Other poster presentations will include preliminary results of BT5528 in combination with nivolumab and studies on EphA2 expression in muscle-invasive bladder cancer, showcasing the company's broad application potential across various cancer types.
- Technological Innovation Context: Bicycle Therapeutics is dedicated to developing Bicycle® molecules, leveraging its unique bicyclic peptide technology to target traditionally undruggable targets like EphA2, demonstrating its innovative capabilities and competitive edge in the oncology market.
See More
Bicycle Therapeutics Restructures and Lays Off 30% of Workforce
- Strategic Restructuring: Bicycle Therapeutics announced a reprioritization of certain programs and a layoff of approximately 30% of its workforce to focus on its most promising candidates, resulting in an expected 50% reduction in annual operating expenses.
- Pipeline Focus: The company will concentrate its research efforts on BT5528 (also known as nuzefatide pevedotin), a potentially first-in-class EphA2-targeting drug conjugate currently in phase I/II clinical trials, aimed at treating metastatic pancreatic ductal adenocarcinoma, indicating strong market potential.
- Clinical Trial Progress: BT5528 is being tested as a monotherapy and in combination with an immune checkpoint inhibitor in phase I/II trials, while also undergoing a phase II trial as a monotherapy for metastatic pancreatic ductal adenocarcinoma, showcasing its potential in cancer treatment.
- Asset De-prioritization: Bicycle Therapeutics will deprioritize its most advanced drug conjugate, zelenectide pevedotin, which targets Nectin-4 expressing tumors and was previously in a phase II trial for metastatic urothelial cancer, reflecting the company's strategic resource allocation adjustments.
See More
Bicycle Therapeutics Q4 Earnings Exceed Expectations
- Strong Earnings Report: Bicycle Therapeutics reported a Q4 GAAP EPS of -$0.29, beating expectations by $0.66, indicating a significant improvement in financial performance and reflecting the potential value of its business model.
- Revenue Surge: The company achieved Q4 revenue of $47.96 million, a staggering 1192.7% year-over-year increase, surpassing market expectations by $40.88 million, demonstrating robust demand and rapid growth for its products or services.
- Healthy Cash Position: As of December 31, 2025, Bicycle Therapeutics holds $628 million in cash and cash equivalents, with an expected cash runway extending into 2030, enhancing the company's flexibility for future investments and operations.
- Strategic Restructuring Plan: The company plans to reduce its workforce by approximately 30% to optimize resource allocation and improve operational efficiency, a move that not only helps lower costs but may also enhance the company's long-term sustainability in the competitive biopharmaceutical industry.
See More
Bicycle Therapeutics Appoints New CFO
- Executive Changes: Bicycle Therapeutics has appointed Travis Thompson as the new Chief Financial Officer, who previously served as the company's Senior Vice President and Chief Accounting Officer, continuing to oversee finance and accounting functions while taking on investor relations, which is expected to enhance communication efficiency with investors.
- Interim Transition Plan: Former CFO Alethia Young will remain in an interim capacity for the next three months before transitioning to a company advisor role, a move designed to ensure continuity and stability in financial management while mitigating potential risks associated with executive turnover.
- Medical and Technology Leadership Adjustments: The company has also promoted Michael Method to Chief Medical Officer, while Michael Skynner, Ph.D., is transitioning to Chief Scientific Officer, which will strengthen the company's leadership in research and development and drive innovation.
- Strategic Restructuring: These executive changes reflect Bicycle Therapeutics' strategic emphasis on enhancing financial, medical, and technological management, aiming to support the company's long-term growth objectives through an optimized leadership team.
See More
Bicycle Therapeutics Signs 15-Year Contract with UK NDA for 400 Tonnes of Reprocessed Uranium
- Strategic Partnership: Bicycle Therapeutics has signed a 15-year contract with the UK Nuclear Decommissioning Authority to access up to 400 tonnes of reprocessed uranium, which is expected to provide a sustainable supply of 212Pb for its potential lifesaving therapies, significantly enhancing its competitive edge in the radiopharmaceutical sector.
- Technological Innovation: Through collaboration with the UK National Nuclear Laboratory, Bicycle plans to extract 228Th from the reprocessed uranium and further process it into 224Ra, developing a bespoke 212Pb generator that will drive the development of its radioconjugate portfolio.
- Market Potential: Bicycle's radioconjugates (BRCs) will utilize 212Pb as a potent therapeutic payload against cancer, expected to offer new treatment options for cancer patients worldwide, presenting significant market opportunities and societal impact.
- R&D Progress: Bicycle aims to present initial EphA2 human imaging data in the first half of 2026 and initiate its own clinical study, marking ongoing advancements in radiopharmaceutical development and establishing its position as a potential leader in the field.
See More
Bicycle Therapeutics Reports Q1 Earnings Miss
- Earnings Report Disappointment: Bicycle Therapeutics reported a Q1 GAAP EPS of -$0.87, missing estimates by $0.20, indicating ongoing challenges in profitability that could undermine investor confidence.
- Significant Revenue Decline: The company generated $0.89M in revenue for Q1, a staggering 91.1% year-over-year drop, falling short of expectations by $6.61M, which highlights severe deficiencies in market demand and product sales that may lead to liquidity issues in the future.
- Cash Reserves Status: As of March 31, 2026, Bicycle Therapeutics held $559.5M in cash and cash equivalents, with an expected runway into 2030, providing a buffer for operations despite current financial strains.
- Strategic Shift and Layoffs: The company announced a shift in priorities and layoffs, indicating proactive measures to address its financial challenges, aiming to enhance operational efficiency through optimized resource allocation.
See More
Bicycle Therapeutics Presents Five Abstracts at AACR Annual Meeting 2026
- Presentation Schedule: Bicycle Therapeutics will showcase five studies at the AACR Annual Meeting 2026 from April 17-22, highlighting its latest advancements in cancer therapeutics, which is expected to attract industry attention and enhance the company's visibility.
- Key Research Findings: One oral presentation will focus on the anti-tumor activity of BT5528 in head and neck squamous cell carcinoma models, demonstrating its potential in preclinical studies and possibly laying the groundwork for subsequent clinical trials.
- Diverse Research Topics: Other poster presentations will include preliminary results of BT5528 in combination with nivolumab and studies on EphA2 expression in muscle-invasive bladder cancer, showcasing the company's broad application potential across various cancer types.
- Technological Innovation Context: Bicycle Therapeutics is dedicated to developing Bicycle® molecules, leveraging its unique bicyclic peptide technology to target traditionally undruggable targets like EphA2, demonstrating its innovative capabilities and competitive edge in the oncology market.
See More
Bicycle Therapeutics Restructures and Lays Off 30% of Workforce
- Strategic Restructuring: Bicycle Therapeutics announced a reprioritization of certain programs and a layoff of approximately 30% of its workforce to focus on its most promising candidates, resulting in an expected 50% reduction in annual operating expenses.
- Pipeline Focus: The company will concentrate its research efforts on BT5528 (also known as nuzefatide pevedotin), a potentially first-in-class EphA2-targeting drug conjugate currently in phase I/II clinical trials, aimed at treating metastatic pancreatic ductal adenocarcinoma, indicating strong market potential.
- Clinical Trial Progress: BT5528 is being tested as a monotherapy and in combination with an immune checkpoint inhibitor in phase I/II trials, while also undergoing a phase II trial as a monotherapy for metastatic pancreatic ductal adenocarcinoma, showcasing its potential in cancer treatment.
- Asset De-prioritization: Bicycle Therapeutics will deprioritize its most advanced drug conjugate, zelenectide pevedotin, which targets Nectin-4 expressing tumors and was previously in a phase II trial for metastatic urothelial cancer, reflecting the company's strategic resource allocation adjustments.
See More
Bicycle Therapeutics Q4 Earnings Exceed Expectations
- Strong Earnings Report: Bicycle Therapeutics reported a Q4 GAAP EPS of -$0.29, beating expectations by $0.66, indicating a significant improvement in financial performance and reflecting the potential value of its business model.
- Revenue Surge: The company achieved Q4 revenue of $47.96 million, a staggering 1192.7% year-over-year increase, surpassing market expectations by $40.88 million, demonstrating robust demand and rapid growth for its products or services.
- Healthy Cash Position: As of December 31, 2025, Bicycle Therapeutics holds $628 million in cash and cash equivalents, with an expected cash runway extending into 2030, enhancing the company's flexibility for future investments and operations.
- Strategic Restructuring Plan: The company plans to reduce its workforce by approximately 30% to optimize resource allocation and improve operational efficiency, a move that not only helps lower costs but may also enhance the company's long-term sustainability in the competitive biopharmaceutical industry.
See More
Bicycle Therapeutics Appoints New CFO
- Executive Changes: Bicycle Therapeutics has appointed Travis Thompson as the new Chief Financial Officer, who previously served as the company's Senior Vice President and Chief Accounting Officer, continuing to oversee finance and accounting functions while taking on investor relations, which is expected to enhance communication efficiency with investors.
- Interim Transition Plan: Former CFO Alethia Young will remain in an interim capacity for the next three months before transitioning to a company advisor role, a move designed to ensure continuity and stability in financial management while mitigating potential risks associated with executive turnover.
- Medical and Technology Leadership Adjustments: The company has also promoted Michael Method to Chief Medical Officer, while Michael Skynner, Ph.D., is transitioning to Chief Scientific Officer, which will strengthen the company's leadership in research and development and drive innovation.
- Strategic Restructuring: These executive changes reflect Bicycle Therapeutics' strategic emphasis on enhancing financial, medical, and technological management, aiming to support the company's long-term growth objectives through an optimized leadership team.
See More
Bicycle Therapeutics Signs 15-Year Contract with UK NDA for 400 Tonnes of Reprocessed Uranium
- Strategic Partnership: Bicycle Therapeutics has signed a 15-year contract with the UK Nuclear Decommissioning Authority to access up to 400 tonnes of reprocessed uranium, which is expected to provide a sustainable supply of 212Pb for its potential lifesaving therapies, significantly enhancing its competitive edge in the radiopharmaceutical sector.
- Technological Innovation: Through collaboration with the UK National Nuclear Laboratory, Bicycle plans to extract 228Th from the reprocessed uranium and further process it into 224Ra, developing a bespoke 212Pb generator that will drive the development of its radioconjugate portfolio.
- Market Potential: Bicycle's radioconjugates (BRCs) will utilize 212Pb as a potent therapeutic payload against cancer, expected to offer new treatment options for cancer patients worldwide, presenting significant market opportunities and societal impact.
- R&D Progress: Bicycle aims to present initial EphA2 human imaging data in the first half of 2026 and initiate its own clinical study, marking ongoing advancements in radiopharmaceutical development and establishing its position as a potential leader in the field.
See More
